Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs State Street Technology Select Sector SPDR ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $299.29 (market cap $8.04B), while State Street Technology Select Sector SPDR ETF trades at $180.07. The key difference: State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| BIO | XLK | |
|---|---|---|
Market Cap | $8.04B | — |
Sector | Health | Sector/Thematic |
52-Week High | $339.75 | $198.21 |
52-Week Low | $241.71 | $127.49 |
Enterprise Value | $7.85B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
XLK trades at $181.28, down 2.43% on the day, with technical indicators showing a bearish moving average trend but neutral oscillators. The ETF has delivered strong year-to-date performance, gaining 33% as of July 2, 2026 (ETF Trends), driven by technology sector leadership. Recent news highlights robust Q2 earnings expectations and institutional inflows into tech ETFs.
Outlook remains cautiously optimistic given sector momentum and earnings growth projections, though risks include market concentration and valuation concerns. The neutral technical signal suggests near-term consolidation, while fundamental strength in tech supports long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
